ZyCoV-D is the first DNA plasmid vaccine in the world for human use, developed indigenously by the Company against the Covid-19 virus. It is also the first COVID-19 vaccine for adolescents in the 12-18 age group, besides the adult population and is a needle-free vaccine administered using The PharmaJet® a needle free applicator, which ensures painless intradermal vaccine delivery. The Company will transfer the ZyCoV-D technology to SBPL. Under the agreement, SBPL will be responsible for manufacture of the drug substance of the vaccine, while the Company is responsible for filling / packaging / distribution / marketing of the vaccine in its marketing territories.